Meta-analysis of the association of IL2RA polymorphisms rs2104286 and rs12722489 with multiple sclerosis risk
- PMID: 29648897
- DOI: 10.1080/08820139.2018.1425699
Meta-analysis of the association of IL2RA polymorphisms rs2104286 and rs12722489 with multiple sclerosis risk
Abstract
Background: The interleukin-2 receptor alpha (IL2RA) gene polymorphisms may be implicated in the genetic susceptibility to multiple sclerosis (MS). This meta-analysis aims to evaluate the relationship of the IL2RA polymorphisms rs2104286 and rs12722489 with MS risk in different populations.
Methods: Eligible association studies were identified through search in Pubmed, Medline, Web of Science, and Scopus (end of search: August 2017). Summary odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-effects or fixed-effects models. All statistical analyses were two-sided.
Results: Eleven studies including 8608 cases and 9061 controls evaluated rs2104286. The results demonstrated that the A allele of rs2104286 was associated with increased risk of MS in Caucasians (OR = 1.19, 95%CI: 1.13-1.25, p < 0.001) and Asians (OR = 1.25, 95%CI: 1.01-1.55, p = 0.041), respectively. Concerning rs12722489, six studies with 4259 cases and 5420 controls were eligible. We found that the C allele of rs12722489 was associated with elevated MS risk in Caucasians (OR = 1.20, 95% CI: 1.12-1.29, p < 0.001) but not in Asians (OR = 1.10, 95%CI: 0.75-1.63, p = 0.629). Statistical evidence from the Egger and Begg tests showed absence of publication bias. Sensitivity analysis showed that the results were stable.
Conclusion: Our meta-analysis suggests that the rs2104286 A allele is associated with increased MS risk in both Caucasians and Asians, whereas the rs12722489 C allele is associated with elevated MS risk in Caucasians but not in Asians.
Keywords: IL2RA; meta-analysis; multiple sclerosis.
Similar articles
-
A genetic link between CXCR5 and IL2RA gene polymorphisms and susceptibility to multiple sclerosis.Neurol Res. 2018 Dec;40(12):1040-1047. doi: 10.1080/01616412.2018.1517110. Neurol Res. 2018. PMID: 30352019
-
Interleukin 2 receptor α gene polymorphism and risk of multiple sclerosis: a meta-analysis.J Int Med Res. 2011;39(5):1625-35. doi: 10.1177/147323001103900505. J Int Med Res. 2011. PMID: 22117963
-
Association of IL2RA and multiple sclerosis risk: A case control, systematic review, and meta-analysis study.J Neurol Sci. 2025 May 15;472:123461. doi: 10.1016/j.jns.2025.123461. Epub 2025 Mar 10. J Neurol Sci. 2025. PMID: 40086235
-
Interleukin 2 receptor α chain gene polymorphisms and risks of multiple sclerosis and neuromyelitis optica in southern Japanese.J Neurol Sci. 2014 Feb 15;337(1-2):147-50. doi: 10.1016/j.jns.2013.11.037. Epub 2013 Dec 4. J Neurol Sci. 2014. PMID: 24332945
-
Interleukin 7 receptor polymorphisms and the risk of multiple sclerosis: A meta-analysis.Mult Scler Relat Disord. 2016 Jul;8:66-73. doi: 10.1016/j.msard.2016.05.001. Epub 2016 May 2. Mult Scler Relat Disord. 2016. PMID: 27456877 Review.
Cited by
-
Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy.Cancers (Basel). 2021 Mar 18;13(6):1370. doi: 10.3390/cancers13061370. Cancers (Basel). 2021. PMID: 33803602 Free PMC article.
-
Analysis of herpesvirus infection and genome single nucleotide polymorphism risk factors in multiple sclerosis, Volga federal district, Russia.Front Immunol. 2022 Nov 14;13:1010605. doi: 10.3389/fimmu.2022.1010605. eCollection 2022. Front Immunol. 2022. PMID: 36451826 Free PMC article.
-
C6orf10 Low-Frequency and Rare Variants in Italian Multiple Sclerosis Patients.Front Genet. 2019 Jun 26;10:573. doi: 10.3389/fgene.2019.00573. eCollection 2019. Front Genet. 2019. PMID: 31297130 Free PMC article.
-
The Role of Selected Interleukins in the Development and Progression of Multiple Sclerosis-A Systematic Review.Int J Mol Sci. 2024 Feb 23;25(5):2589. doi: 10.3390/ijms25052589. Int J Mol Sci. 2024. PMID: 38473835 Free PMC article.
-
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.J Immunother Cancer. 2020 May;8(1):e000586. doi: 10.1136/jitc-2020-000586. J Immunother Cancer. 2020. PMID: 32461348 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical